Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 1.27
08/11/2023 11:50
Nov 08 (Reuters) - ANI Pharmaceuticals Q3 revenue USD 131.829 million. * Q3 operating expenses USD 113.881 million * Q3 operating income USD 17.948 million * Q3 net income USD 9.94 million * outlook FY adjusted EPS USD 4.29-4.57 * outlook FY adjusted EBITDA USD 128-133 million
Recent news on ANI Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
ANI Pharmaceuticals Q1 revenue rises 21%, adjusted EPS beats estimates
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma